Cytomegaloviral Control of MHC Class I Function in the Mouse
Overview
General Surgery
Affiliations
Cytomegaloviruses (CMVs) represent prototypic viruses of the beta-subgroup of herpesviruses. Murine cytomegalovirus (MCMV) infects mice as its natural host. Among viruses, CMVs have evolved the most extensive genetic repertoire to subvert MHC class I functions. To date three MCMV proteins have been identified which affect MHC I complexes. They are encoded by members of large virus-specific gene families located at either flanking region of the 235 kb MCMV genome. The MHC I subversive genes belong to the early class of genes and code for type I transmembrane glycoproteins. The m152-encoded 37/40 kDa glycoprotein interacts with MHC I transiently and retains class I complexes in the endoplasmic reticulum (ER) Golgi intermediate compartment on its journey to the endolysosome. In contrast, the m06-encoded glycoprotein of 48 kDa complexes tightly with ternary MHC class I molecules in the FR. Due to sorting signals in its cytoplasmic tail, gp48 redirects MHC I to endolysosomal compartments for proteolytic destruction. Likewise, the 34 kDa glycoprotein encoded by m04 binds tightly to MHC class I complexes in the ER but the gp34/MHC I complex reaches the plasma membrane. The CD8+ T-cell-dependent attenuation of a m152 deletion mutant virus proves for the first time that inhibition of antigen presentation is indeed essential for the biological fitness of CMVs in vivo.
Li F, Deng J, He Q, Zhong Y Front Immunol. 2023; 14:1091766.
PMID: 36845119 PMC: 9950778. DOI: 10.3389/fimmu.2023.1091766.
Holtappels R, Podlech J, Freitag K, Lemmermann N, Reddehase M Viruses. 2022; 14(6).
PMID: 35746617 PMC: 9229300. DOI: 10.3390/v14061145.
Xu J, Liu X, Zhang X, Marshall B, Dong Z, Smith S Am J Pathol. 2021; 191(10):1787-1804.
PMID: 34197777 PMC: 8485058. DOI: 10.1016/j.ajpath.2021.06.008.
Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines.
Boppana S, Britt W Methods Mol Biol. 2021; 2244:403-463.
PMID: 33555597 DOI: 10.1007/978-1-0716-1111-1_19.
Overcoming innate immune barriers that impede AAV gene therapy vectors.
Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald K, Tai P J Clin Invest. 2021; 131(1).
PMID: 33393506 PMC: 7773343. DOI: 10.1172/JCI143780.